Skip to Content

Vectibix Approval History

  • FDA approved: Yes (First approved September 27th, 2006)
  • Brand name: Vectibix
  • Generic name: panitumumab
  • Dosage form: Injection
  • Company: Amgen Inc.
  • Treatment for: Colorectal Cancer

Vectibix (panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer.

Development History and FDA Approval Process for Vectibix

Jun 29, 2017Approval FDA Approves Vectibix (panitumumab) for Use in Wild-Type RAS Metastatic Colorectal Cancer
May 23, 2014Approval FDA Approves First-Line Use of Vectibix (panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer
Sep 27, 2006Approval FDA Approves Vectibix (panitumumab) to Treat Patients with Metastatic Colorectal Cancer
Mar 30, 2006Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.